UNSPSC 51292306: Tropanserin hydrochloride

This classification denotes a serotonin antagonist with the molecular formula C17H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6R9A98I18O, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3,5-dimethylbenzoate, hydrochloride but more generally known as tropanserin hydrochloride, which bears US NIH Compound Identifier 68599. Most nations, for tariff and trade purposes, schedule tropanserin hydrochloride under HS 29399900 and SITC 54149.

As of Q4 2014, TROPANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tropanserin hydrochloride bears US NLM identifiers UMLS ID C2987003 and NCI Concept Code C95219. SMILES: CC1CC(CC(C1)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)C.CL.

UNSPSC 51292306 Tropanserin hydrochloride (Commodity) does not align with the state and local procurement activity currently tagged under this code. The recent opportunities include naloxone procurement, a direct-to-manufacturer prescription program, and generic multi-source pharmaceuticals and over-the-counter products — none of which involve tropanserin hydrochloride. The code shows no relevant recent activity supporting active demand for this specific pharmaceutical.

State and local agencies soliciting under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Activity is geographically distributed across Florida, Texas, and the upper Midwest, though the pharmaceutical procurement landscape suggests that state and local demand is organized primarily through cooperative purchasing vehicles and statewide health agency channels rather than direct individual-jurisdiction buys. Representatives of recent competitive activity include Seminole County's IFB for naloxone and drug deactivation systems (response due July 26, 2023) and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026), both of which reflect commodity-level pharmaceutical supply rather than a targeted specialty pharmaceutical like tropanserin hydrochloride.